Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $0.73 down -3.11% from its previous closing price of $0.75. In other words, the price has decreased by -$3.11 from its previous closing price. On the day, 3.33 million shares were traded. IRWD stock price reached its highest trading level at $0.7801 during the session, while it also had its lowest trading level at $0.7002.
Ratios:
For a deeper understanding of Ironwood Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1.14. For the most recent quarter (mrq), Quick Ratio is recorded 4.69 and its Current Ratio is at 4.69.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 10 ’25 when MCCOURT Thomas A sold 139,064 shares for $1.76 per share. The transaction valued at 244,753 led to the insider holds 1,160,634 shares of the business.
Silver Ronald sold 12,048 shares of IRWD for $21,204 on Feb 10 ’25. The Principal Accounting Officer now owns 279,655 shares after completing the transaction at $1.76 per share. On Feb 10 ’25, another insider, Shetzline Michael, who serves as the SVP, CMO, Head-Res&Drug of the company, sold 41,269 shares for $1.76 each. As a result, the insider received 72,633 and left with 554,007 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 117586592 and an Enterprise Value of 628508928. As of this moment, Ironwood’s Price-to-Earnings (P/E) ratio for their current fiscal year is 67.29, and their Forward P/E ratio for the next fiscal year is 2.15. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.33. Its current Enterprise Value per Revenue stands at 1.789 whereas that against EBITDA is 6.431.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.55, which has changed by -0.9094293 over the last 52 weeks, in comparison to a change of 0.05430484 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $8.45, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is -51.10%, while the 200-Day Moving Average is calculated to be -80.72%.
Shares Statistics:
For the past three months, IRWD has traded an average of 3.87M shares per day and 6267270 over the past ten days. A total of 160.21M shares are outstanding, with a floating share count of 156.66M. Insiders hold about 3.18% of the company’s shares, while institutions hold 101.60% stake in the company. Shares short for IRWD as of 1743379200 were 11250189 with a Short Ratio of 2.91, compared to 1740700800 on 12052713. Therefore, it implies a Short% of Shares Outstanding of 11250189 and a Short% of Float of 13.3.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Ironwood Pharmaceuticals Inc (IRWD) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.03, with high estimates of $0.04 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.22 and $0.1 for the fiscal current year, implying an average EPS of $0.16. EPS for the following year is $0.42, with 4.0 analysts recommending between $1.12 and $0.03.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $66.77M this quarter.It ranges from a high estimate of $79.9M to a low estimate of $56M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $74.88MFor the next quarter, 6 analysts are estimating revenue of $72.03M. There is a high estimate of $99.9M for the next quarter, whereas the lowest estimate is $64M.
A total of 6 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $376M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $287.07M. In the same quarter a year ago, actual revenue was $351.41MBased on 5 analysts’ estimates, the company’s revenue will be $308.36M in the next fiscal year. The high estimate is $534M and the low estimate is $223.6M.
